INCY
Incyte Corporation
INCY
Incyte Corporation
Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth,
Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.